Genentech earnings leap; analysts yawn

Genentech ended 2008 with a bang. Earnings leapt by 47 percent for the fourth quarter to $931 million, or 87 cents per share, on revenue growth of 25 percent. At $3.7 billion, revenues included $2.98 billion in drug sales.

Nevertheless, Wall Street greeted the news with a thud. Analysts had expected earnings of 97 cents per share, for one thing. For another, Genentech's outlook for 2009 was distressing. It will be a "difficult year to forecast," the company said,  because of the economy and "business uncertainties." The Street had expected a forecast of $3.92 per share, but Genentech says it's looking for $3.55 to $3.90. That's quite a range.

The question marks ahead for Genentech include upcoming data on Avastin's utility in early colorectal cancer, plus worries about PML infections that have arisen in Raptiva patients, the Wall Street Journal points out. Of course the biggest question remains whether Roche will pull off its buyout of the 44 percent of Genentech it doesn't already own.

- view Genentech's release
- see the story at MarketWatch
- check out the WSJ article

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.